Active Clinical Trials

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

By April 24, 2017 No Comments


Tumors With CDK4/6 Pathway Activation

Estimated Enrollment: 106

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CLEE011XUS03

Study First Received: July 9, 2014

Last Updated: November 27, 2016

Estimated Primary Completion Date: April 2018


Primary Outcome Measures:

Clinical benefit rate associated with LEE011 treatment|Overall Response (OR) of Partial Response (PR) or greater|Progression Free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Safety and tolerability

Sponsors and Collaborators:

Novartis Pharmaceuticals|Novartis

Website Link:

Leave a Reply

Call Now